NSPR - InspireMD Inc Stock Price, Fair Value and News

2.30USD0.00 (0.00%)Market Closed

Market Summary

USD2.300.00

Market Closed

0.00%

NSPR Stock Price

View Fullscreen

NSPR RSI Chart

NSPR Valuation

Market Cap

57.3M

Price/Earnings (Trailing)

-2.53

Price/Sales (Trailing)

8.85

EV/EBITDA

-2.44

Price/Free Cashflow

-3.34

NSPR Price/Sales (Trailing)

NSPR Profitability

Operating Margin

62.48%

EBT Margin

-306.48%

Return on Equity

-64.67%

Return on Assets

-53.99%

Free Cashflow Yield

-29.93%

NSPR Fundamentals

NSPR Revenue

Revenue (TTM)

6.5M

Rev. Growth (Yr)

21.95%

Rev. Growth (Qtr)

-14.2%

NSPR Earnings

Earnings (TTM)

-22.7M

Earnings Growth (Yr)

-65.23%

Earnings Growth (Qtr)

-30.1%

Breaking Down NSPR Revenue

Last 7 days

3.1%

Last 30 days

4.1%

Last 90 days

-13.2%

Trailing 12 Months

35.3%

How does NSPR drawdown profile look like?

NSPR Financial Health

Current Ratio

7.9

Debt/Equity

0.03

Debt/Cashflow

-15.11

NSPR Investor Care

Shares Dilution (1Y)

198.33%

Diluted EPS (TTM)

-0.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.5M	0	0	0
2023	5.2M	5.3M	5.5M	6.2M
2022	4.7M	5.2M	5.5M	5.2M
2021	2.5M	3.2M	3.3M	4.5M
2020	4.3M	3.3M	3.3M	2.5M
2019	3.0M	3.4M	3.5M	3.7M
2018	3.2M	3.6M	3.6M	3.6M
2017	1.9M	2.0M	2.2M	2.8M
2016	2.4M	2.3M	2.1M	1.9M
2015	1.8M	2.3M	2.7M	2.3M
2014	6.1M	4.8M	3.5M	2.8M
2013	4.3M	4.9M	5.9M	6.1M
2012	5.5M	5.3M	3.9M	3.9M
2011	4.5M	4.7M	5.4M	6.0M
2010	0	3.9M	4.4M	4.9M
2009	0	0	0	3.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of InspireMD Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 23, 2024	shore craig	acquired	-	-	238,625	cfo and cao
Jan 23, 2024	berman michael	acquired	-	-	29,032	-
Jan 23, 2024	kester thomas j	acquired	-	-	29,032	-
Jan 23, 2024	slosman marvin	acquired	-	-	563,499	ceo and president
Jan 23, 2024	verta patrick	acquired	-	-	85,720	evp clinical/medical affairs
Jan 23, 2024	roubin gary s	acquired	-	-	29,032	-
Jan 23, 2024	gleason shane thomas	acquired	-	-	238,625	chief commercial officer
Jan 23, 2024	tommasoli andrea	acquired	-	-	238,625	chief operating officer
Jan 23, 2024	stuka paul	acquired	-	-	43,548	-
Jan 23, 2024	arnold kathryn	acquired	-	-	29,032	-

Which funds bought or sold NSPR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	-27,947	150,572	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	3,000	-%
May 15, 2024	ORBIMED ADVISORS LLC	unchanged	-	-938,485	5,056,380	0.09%
May 15, 2024	NOTTINGHAM ADVISORS, INC.	added	20.00	853	71,103	0.01%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	unchanged	-	-1.00	2.00	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	21.06	-8,903	969,747	-%
May 15, 2024	MARSHALL WACE, LLP	unchanged	-	-948,806	4,278,930	0.01%
May 15, 2024	Jetstream Capital LLC	new	-	82,954	82,954	3.60%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-50.00	-6,715,780	4,897,710	0.28%
May 15, 2024	PURA VIDA INVESTMENTS, LLC	unchanged	-	-198,183	1,067,770	0.18%

Are Funds Buying or Selling NSPR?

Are funds buying NSPR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NSPR

No. of Funds

Unveiling InspireMD Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	9.9%	686,062	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	9.9%	2,162,392	SC 13G
Feb 14, 2024	rosalind advisors, inc.	9.9%	989,940	SC 13G/A
Feb 14, 2024	orbimed advisors llc	9.9%	2,133,405	SC 13G
Jun 16, 2023	shore craig	8.01%	1,700,159	SC 13D
Jun 08, 2023	rosalind advisors, inc.	9.9%	1,860,405	SC 13G
May 24, 2023	soleus private equity fund iii, l.p.	9.9%	2,199,118	SC 13G
May 22, 2023	marshall wace north america l.p.	9.9%	1,860,405	SC 13G
Feb 11, 2022	lind global macro fund lp	2.1%	177,333	SC 13G/A
Feb 09, 2021	lind global macro fund lp	5.3%	2,055,163	SC 13G/A

Recent SEC filings of InspireMD Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	SC 13G/A	Major Ownership Report
May 14, 2024	8-K	Current Report
May 13, 2024	10-Q	Quarterly Report
Apr 25, 2024	SC 13G/A	Major Ownership Report
Apr 18, 2024	DEFA14A	DEFA14A
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	ARS	ARS
Apr 02, 2024	8-K	Current Report
Mar 26, 2024	8-K	Current Report
Mar 06, 2024	8-K	Current Report

Peers (Alternatives to InspireMD Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

InspireMD Inc News

Latest updates

InspireMD Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-14.2%	1,511,000	1,761,000	1,556,000	1,649,000	1,239,000	1,026,000	1,431,000	1,531,000	1,183,000	1,380,000	1,071,000	1,038,000	1,006,000	158,000	980,000	313,000	1,034,000	1,013,000	939,000	1,354,000	415,000
Gross Profit	-42.2%	292,000	505,000	438,000	491,000	373,000	198,000	366,000	431,000	122,000	294,000	92,000	262,000	106,000	-390,000	298,000	-120,000	295,000	259,000	128,000	442,000	-73,000
Operating Expenses	22.1%	7,706,000	6,313,000	6,077,000	5,806,000	4,754,000	5,134,000	4,976,000	5,112,000	4,608,000	4,225,000	4,123,000	3,702,000	3,420,000	3,328,000	2,493,000	2,326,000	2,316,000	2,765,000	2,125,000	2,625,000	3,057,000
S&GA Expenses	-5.5%	1,237,000	1,309,000	876,000	892,000	788,000	1,087,000	845,000	986,000	746,000	761,000	802,000	636,000	708,000	617,000	485,000	377,000	624,000	605,000	537,000	620,000	634,000
R&D Expenses	29.0%	2,625,000	2,035,000	2,110,000	1,993,000	1,843,000	2,013,000	2,061,000	2,056,000	1,680,000	1,534,000	1,495,000	1,290,000	839,000	720,000	546,000	444,000	523,000	522,000	442,000	865,000	1,125,000
EBITDA Margin	4.2%	-3.03	-3.16	-3.23	-3.30	-3.38	-3.42	-3.07	-3.19	-3.29	-3.14	-3.00	-3.08	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-4,817,000	-4,529,000	-4,636,000	-4,481,000	-4,052,000	-4,071,000	-3,507,000	-3,243,000	-	-	-2,480,000	-	-2,533,000	-2,070,000	-2,206,000	-3,207,000
EBT Margin	4.2%	-3.06	-3.20	-3.38	-3.45	-3.53	-3.57	-3.20	-3.34	-3.45	-3.31	-3.22	-3.31	-	-	-	-	-	-	-	-	-
Net Income	-30.1%	-7,032,000	-5,405,000	-5,178,000	-5,077,000	-4,256,000	-4,845,000	-4,529,000	-4,636,000	-4,481,000	-4,097,000	-4,071,000	-3,507,000	-3,243,000	-3,853,000	-2,233,000	-2,480,000	-1,978,000	-2,557,000	-2,070,000	-2,206,000	-3,207,000
Net Income Margin	-9.2%	-3.50	-3.21	-3.54	-3.50	-3.49	-3.58	-3.21	-3.35	-3.46	-3.32	-4.48	-4.03	-	-	-	-	-	-	-	-	-
Free Cashflow	-19.7%	-5,259,000	-4,392,000	-4,139,000	-3,370,000	-4,856,000	-3,290,000	-5,330,000	-3,224,000	-4,171,000	-3,008,000	-4,297,000	-2,582,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-11.8%	42.00	48.00	50.00	54.00	20.00	25.00	28.00	33.00	35.00	40.00	43.00	46.00	49.00	18.00	16.00	18.00	7.00	10.00	12.00	9.00	10.00
Current Assets	-12.8%	39.00	44.00	47.00	51.00	17.00	21.00	25.00	30.00	33.00	37.00	40.00	44.00	46.00	15.00	13.00	16.00	5.00	8.00	10.00	7.00	8.00
Cash Equivalents	-2.6%	9.00	10.00	14.00	12.00	4.00	5.00	4.00	6.00	8.00	12.00	13.00	41.00	44.00	13.00	11.00	14.00	3.00	6.00	7.00	5.00	6.00
Inventory	12.1%	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-
Net PPE	11.9%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00
Liabilities	-14.8%	7.00	8.00	7.00	7.00	6.00	7.00	6.00	7.00	5.00	6.00	6.00	6.00	5.00	6.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00
Current Liabilities	-19.0%	5.00	6.00	5.00	5.00	4.00	5.00	4.00	5.00	4.00	4.00	4.00	4.00	3.00	4.00	3.00	3.00	3.00	3.00	2.00	2.00	3.00
Shareholder's Equity	-11.2%	35.00	40.00	43.00	47.00	13.00	17.00	22.00	26.00	30.00	34.00	37.00	41.00	44.00	12.00	11.00	13.00	3.00	5.00	8.00	6.00	6.00
Retained Earnings	-3.2%	-228	-221	-216	-210	-205	-201	-196	-192	-187	-183	-179	-174	-171	-168	-164	-162	-159	-157	-155	-153	-150
Additional Paid-In Capital	1.0%	264	261	259	258	219	219	219	218	217	217	216	216	215	180	176	175	163	163	163	159	156
Shares Outstanding	7.2%	23.00	22.00	21.00	21.00	8.00	8.00	8.00	8.00	8.00	8.00	7.00	8.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	46.00	-	-	-	16.00	-	-	-	39.00	-	-	-	16.00	-	-	-	5.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-21.2%	-5,064	-4,177	-4,043	-3,325	-4,831	-3,195	-5,104	-3,109	-4,134	-2,901	-4,140	-2,528	-3,641	-2,200	-3,044	-1,483	-2,354	-1,568	-1,860	-2,897	-3,485
Share Based Compensation	58.8%	2,618	1,649	1,622	930	289	368	657	674	653	566	304	383	323	345	141	51.00	69.00	40.00	107	110	68.00
Cashflow From Investing	13480.6%	4,817	-36.00	6,386	-26,891	4,449	3,886	2,754	1,866	-65.00	1,841	-24,184	-90.00	-24.00	-104	-49.00	-31.00	-3.00	-69.00	-94.00	-119	-105
Cashflow From Financing	-	-	-	-	37,534	-	-	-103	-	-	-	-35.00	1.00	35,068	4,068	90.00	12,234	3.00	4.00	4,285	2,030	16.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NSPR Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
REVENUES	$ 1,511	$ 1,239
COST OF REVENUES	1,219	866
GROSS PROFIT	292	373
OPERATING EXPENSES:
Research and development	2,625	1,843
Selling and marketing	1,237	788
General and administrative	3,844	2,123
Total operating expenses	7,706	4,754
LOSS FROM OPERATIONS	(7,414)	(4,381)
FINANCIAL INCOME, net	382	125
NET LOSS	$ (7,032)	$ (4,256)
NET LOSS PER SHARE - basic	$ (0.21)	$ (0.53)
NET LOSS PER SHARE - diluted	$ (0.21)	$ (0.53)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic	34,242,976	8,093,340
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - diluted	34,242,976	8,093,340

NSPR Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

CURRENT ASSETS:

Cash and cash equivalents

$ 9,389

$ 9,640

Marketable securities

24,561

29,383

Accounts receivable:

Trade, net

1,187

1,804

Other

483

648

Prepaid expenses

531

578

Inventory

2,360

2,106

TOTAL CURRENT ASSETS

38,511

44,159

NON-CURRENT ASSETS:

Property, plant and equipment, net

1,186

1,060

Operating lease right of use assets

1,366

1,473

Fund in respect of employee rights upon retirement

965

951

TOTAL NON-CURRENT ASSETS

3,517

3,484

TOTAL ASSETS

42,028

47,643

Accounts payable and accruals:

Trade

659

939

Other

4,218

5,081

TOTAL CURRENT LIABILITIES

4,877

6,020

LONG-TERM LIABILITIES-

Operating lease liabilities

914

1,038

Liability for employees rights upon retirement

1,150

1,084

TOTAL LONG-TERM LIABILITIES

2,064

2,122

COMMITMENTS AND CONTINGENT LIABILITIES

TOTAL LIABILITIES

6,941

8,142

EQUITY:

Common stock, par value $0.0001 per share; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023; 23,412,385 and 21,841,215 shares issued and outstanding at March 31, 2024 and December 2023, respectively

Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at March 31, 2024 and December 31, 2023; 1,718 shares issued and outstanding at March 31, 2024 and December 31 2023, respectively

^[1]

Additional paid-in capital

263,618

261,000

Accumulated deficit

(228,533)

(221,501)

Total equity

35,087

39,501

Total liabilities and equity

$ 42,028

$ 47,643

[1]	Represents an amount less than $1 thousand

About InspireMD Inc

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

CEO	Mr. Marvin L. Slosman
WEBSITE	inspiremd.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	55

InspireMD Inc Frequently Asked Questions

What is the ticker symbol for InspireMD Inc? What does NSPR stand for in stocks?

NSPR is the stock ticker symbol of InspireMD Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of InspireMD Inc (NSPR)?

As of Fri May 17 2024, market cap of InspireMD Inc is 57.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NSPR stock?

You can check NSPR's fair value in chart for subscribers.

What is the fair value of NSPR stock?

You can check NSPR's fair value in chart for subscribers. The fair value of InspireMD Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of InspireMD Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NSPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is InspireMD Inc a good stock to buy?

The fair value guage provides a quick view whether NSPR is over valued or under valued. Whether InspireMD Inc is cheap or expensive depends on the assumptions which impact InspireMD Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NSPR.

What is InspireMD Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, NSPR's PE ratio (Price to Earnings) is -2.53 and Price to Sales (PS) ratio is 8.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NSPR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on InspireMD Inc's stock?

In the past 10 years, InspireMD Inc has provided -0.828 (multiply by 100 for percentage) rate of return.